Discover the emerging class of degrader-antibody conjugates – a modality that is drawing increasing interest from biotech ...

Add Yahoo as a preferred source to see more of our stories on Google. Antibody drug conjugates (ADCs) have gained significant momentum in recent years, due to their clinical successes in cancer ...

In this free webinar, gain actionable insights and proven strategies to support more effective navigation of the complexities of antibody-drug conjugate (ADC) clinical development. Attendees will ...

Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy. Antibody-drug conjugates (ADCs) are changing ...

Can WuXi AppTec’s Integrated Discovery Platform Power Oncology? WuXi AppTec’s integrated platform combines high-authority screening, pharmacology, and early assessment in a single end-to-end system.

Tubulis, an antibody-drug conjugate developer based in Germany, said Wednesday it raised a €308 million, or $361 million, Series C round to advance its lead program deeper into human studies. Its top ...

AbbVie announced plans to acquire Immunogen — and the biotech’s recently approved ADC treatment for ovarian cancer — for $10.1 billion in cash. The pharma giant is diving into ADCs again after a ...

Patent covers proprietary 2nd generation Thailanstatin analog payload designed for use in ADCs (antibody-drug conjugates) ...

ADCs have rapidly evolved, with 13 FDA-approved drugs targeting various cancers, improving efficacy and tolerability. Innovations include targeting cancer-specific proteins, enhancing antibody ...

Over the past few years economic headwinds have resulted in fewer deals, with companies and private equity firms alike reassessing where to spend money. But one portion of the pharmaceutical industry ...

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s technology in two candidates. The Czech biotech disclosed the update on the same ...

Despite being a targeted therapy, antibody-drug conjugates (ADCs) can cause significant off-target toxicity to the eyes of patients being treated for advanced multiple myeloma or cervical cancer, yet ...